Renal transplantation in patients with familial Mediterranean fever

Erdem, Emre; Karatas, Ahmet; Kaya, Coskun; Dilek, Melda; Yakupoglu, Yarkın; Arık, Nurol; Akpolat, Tekin
August 2012
Clinical Rheumatology;Aug2012, Vol. 31 Issue 8, p1183
Academic Journal
Amyloidosis is the most common and devastating complication of familial Mediterranean fever (FMF). Renal transplantation is the choice of treatment of in most end-stage renal disease (ESRD). We report our experience on the outcomes in eight patients who underwent renal transplantation for ESRD due to FMF secondary to amyloidosis, and we provide a discussion on the current evidence on this topic of study. The clinical charts of eight renal transplant patients (seven male, one female) who underwent ESRD due to FMF-related amyloidosis were investigated. Five patients underwent living-donor renal transplantation and three patients underwent deceased-donor renal transplant. The mean follow-up period was 35 months (range 3-72). All patients were on triple immunosuppressive treatment and received colchicine. All allografts are currently functioning well with a mean serum creatinine level of 1.4 (range 0.7-2.6) mg/dL. Posttransplantation complications included acute rejection ( n = 4), chronic rejection ( n = 1), severe gastroenteritis ( n = 2), and erythrocytosis ( n = 5). None of the patients had proteinuria. During follow-up, we did not observe clinically severe FMF attack, septicemia, rhabdomylosis, symptoms related to vasculitis, and clinical neuropathy. The clinical outcome of the patients in this cohort was similar to that of other renal transplant patients with ESRD due to other causes. This study shows favorable prognosis of eight ESRD patients due to amyloidosis caused by FMF after renal transplantation. Renal transplantation is a safe procedure for ESRD patients having amyloidosis due to FMF. Regular use of colchicine after transplantation should be mentioned.


Related Articles

  • Serum Amyloid A Protein in Familial Mediterranean Fever. Knecht, Aaron; de Beer, Frederick C.; Pras, Mordechai // Annals of Internal Medicine;Jan85, Vol. 102 Issue 1, p71 

    Presents a case which studied the serum amyloid A levels found in a patients with familial Mediterranean fever during and between attacks, in those with and without amyloid nephropathy and in those receiving colchicine and those left untreated. Distribution of all serum amyloid A; Mean serum...

  • Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Christian Moser; Gudrun Pohl; Isabella Haslinger; Sylvia Knapp; Dorota Rowczenio; Tonia Russel; Helen J. Lachmann; Ursula Lang; Josef Kovarik // Nephrology Dialysis Transplantation;Feb2009, Vol. 24 Issue 2, p676 

    Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by recurrent episodes of fever and inflammation. The most severe complication of FMF is the development of AA amyloidosis, which can be life threatening. The only current effective treatment for FMF is colchicine....

  • AA amyloidosis in the renal allograft: a report of two cases and review of the literature. Rojas, Rebecca; Josephson, Michelle A.; Chang, Anthony; Meehan, Shane M. // Clinical Kidney Journal;Apr2012, Vol. 5 Issue 2, p146 

    AA amyloidosis is a disorder characterized by the abnormal formation, accumulation and systemic deposition of fibrillary material that frequently involves the kidney. Recurrent AA amyloidosis in the renal allograft has been documented in patients with tuberculosis, familial Mediterranean fever,...

  • Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Alpay, Nilüfer; Şumnu, Abdullah; Çalışkan, Yaşar; Yazıcı, Halil; Türkmen, Aydın; Gül, Ahmet // Rheumatology International;Oct2012, Vol. 32 Issue 10, p3277 

    Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by self-limited recurrent attacks of fever and serositis. The serious complication of FMF is AA-type amyloidosis, which can result in end-stage renal disease. Although colchicine is effective in the majority of...

  • The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Calligaris, Lorenzo; Marchetti, Federico; Tommasini, Alberto; Ventura, Alessandro // European Journal of Pediatrics;Jun2008, Vol. 167 Issue 6, p695 

    Colchicine is the treatment of choice in familial Mediterranean fever (FMF) for the prevention of both attacks and secondary amyloidosis. The overall nonresponder rate is about 5–10%. Anakinra is known to have good effectiveness in a severe autoinflammatory syndrome [chronic infantile...

  • Pharmacological and Clinical Basis of Treatment of Familial Mediterranean Fever (FMF) with Colchicine or Analogues: An Update. Cerquaglia, C.; Diaco, M.; Nucera, G.; Regina, M. L.; Montalto, M.; Manna, R. // Current Drug Targets - Inflammation & Allergy;Feb2005, Vol. 4 Issue 1, p117 

    Familial Mediterranean Fever (FMF), an autosomal recessive disorder, is characterised by recurrent attacks of fever and serositis, lasting 24-72 hours. Since 1972 colchicine has become the drug of choice for prophylaxis against FMF attacks and amyloidosis FMF-associated. Colchicine, an alkaloid...

  • Non-canonical manifestations of familial Mediterranean fever: a changing paradigm. Rigante, Donato; Lopalco, Giuseppe; Tarantino, Giusyda; Compagnone, Adele; Fastiggi, Michele; Cantarini, Luca // Clinical Rheumatology;Sep2015, Vol. 34 Issue 9, p1503 

    Paroxysmal crises of fever and systemic inflammation herald familial Mediterranean fever (FMF), considered as the archetype of all inherited systemic autoinflammatory diseases. Inflammatory bouts are characterized by short-term and self-limited abdominal, thoracic, and/or articular symptoms...

  • Long-term colchicine prophylaxis in familial Mediterranean fever. Levy, M.; Eliakim, M. // British Medical Journal;9/24/1977, Vol. 2 Issue 6090, p808 

    Investigates the long-term colchicine prophylaxis in familial Mediterranean fever (FMF). Administration of extensive laboratory investigations; Effect of colchicine on the growth of patients; Prevalence of amyloidosis in patients with FMF.

  • CYP3A5 Genotype Markedly Influences the Pharmacokinetics of Tacrolimus and Sirolimus in Kidney Transplant Recipients. Renders, L.; Frisman, M.; Ufer, M.; Mosyagin, I.; Haenisch, S.; Ott, U.; Caliebe, A.; Dechant, M.; Braun, F.; Kunzendorf, U.; Cascorbi, I. // Clinical Pharmacology & Therapeutics;Feb2007, Vol. 81 Issue 2, p228 

    It is currently not clear whether the concentration–time curves of the immunosuppressants differ with respect to the CYP3A5, MDR1, or MRP2 genotype in dose-adapted stable kidney transplant patients. Dose/trough concentration ratios were obtained in 134 tacrolimus and 20 sirolimus-treated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics